01 9Adalat
02 1AdalatTM
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 741
2019 Revenue in Millions : 803
Growth (%) : -8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 840
2020 Revenue in Millions : 741
Growth (%) : 24
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 873
2021 Revenue in Millions : 840
Growth (%) : 4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 611
2022 Revenue in Millions : 873
Growth (%) : -32
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 647
2014 Revenue in Millions : 696
Growth (%) : 8%
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : -2.50%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 804
2016 Revenue in Millions : 774
Growth (%) : 4
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 661
2015 Revenue in Millions : 671
Growth (%) : -1
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 690
2017 Revenue in Millions : 732
Growth (%) : -6%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 724
2018 Revenue in Millions : 666
Growth (%) : 9
LOOKING FOR A SUPPLIER?